Association of the MDR1 Variants (rs2032582 and rs2032583) with Steroid Response in Iraqi Children with Idiopathic Nephrotic Syndrome

Ali Mohammed Abd Alridha; Dheyaa Jabbar Kadhim; Ayad Hussein Ali Alkhazrajy

doi:10.54133/ajms.v6i2.944

Authors

Ali Mohammed Abd Alridha Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, University of Kufa, Najaf, Iraq https://orcid.org/0000-0002-5580-9849
Dheyaa Jabbar Kadhim Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq https://orcid.org/0000-0002-2654-1441
Ayad Hussein Ali Alkhazrajy Babylon Hospital for Maternity and Pediatrics, Babylon, Iraq https://orcid.org/0000-0003-2525-5117

DOI:

https://doi.org/10.54133/ajms.v6i2.944

Keywords:

Genetic polymorphisms, Iraq, MDR1, Nephrotic syndrome, Steroid resistance

Abstract

Background: Several studies linked the development of steroid-resistant nephrotic syndrome (SRNS) to genetic variations in the multidrug resistance 1 (MDR1) gene, though a disparity in findings was underlined among children with different ethnic origins. Objective: This study examined the relationship between MDR1 variants (rs2032582 and rs2032583) and the risk of developing SRNS in Iraqi patients with idiopathic nephrotic syndrome (INS). Methods: This case-control study included children with steroid-sensitive INS (SSNS; n=30) and SRNS (n=30) from the Babylon Hospital for Maternity and Pediatrics. Sanger sequencing was used to determine the participants’ genotypes. Results: The rs2032582 genotypes and alleles were not associated with SRNS development risk. It was also found that kids who had both the wild or mutant homozygous genotypes for rs2032583 and rs2032582 variants were more likely to get SRNS [OR (95%CI):30.18 (1.55–588.5), p=0.008] than kids who had both the heterozygous genotypes for rs2032583 and either genotype of rs2032582. Conclusions: Nephrotic children who have homozygous genotypes (wild or mutant) for the rs2032583 and rs2032582 variants likely resist prednisolone therapy, and an alternative therapeutic regimen may be warranted. Further investigations are needed to elucidate the potential implications of MDR1 variants for personalizing drug therapy in INS children.

Downloads

Download data is not yet available.

References

Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018;392(10141):61-74. doi: 10.1016/S0140-6736(18)30536-1.

Naif MH, Mohammed TF. Clinicopathological features of primary nephrotic syndrome in Iraqi children. Iraqi Postgrad Med J. 2019;65(2):155–160.

Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362(9384):629–39.doi: 10.1016/S0140-6736(03)14184-0

Davin JC, Rutjes NW. Nephrotic syndrome in children: from bench to treatment. Int J Nephrol. 2011;2011:372304. doi: 10.4061/2011/372304.

Pasini A, Benetti E, Conti G, Ghio L, Lepore M, Massella L, et al. The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I - Diagnosis and treatment of the first episode and the first relapse. Ital J Pediatr. 2017;43(1):41. doi: 10.1186/s13052-017-0356-x.

Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1–276. doi: 10.1016/j.kint.2021.05.021.

Hjorten R, Anwar Z, Reidy KJ. Long-term outcomes of childhood onset nephrotic syndrome. Front Pediatr. 2016;4:53. doi: 10.3389/fped.2016.00053.

Banaszak B, Banaszak P. The increasing incidence of initial steroid resistance in childhood nephrotic syndrome. Pediatr Nephrol. 2012;27(6):927–32. doi: 10.1007/s00467-011-2083-7.

Kumar J, Sarwar B, Kishan J, Khan AR, Abdullah MA, Shah SS. Changing Histopathological Trends in Idiopathic Steroid Resistant Nephrotic Syndrome in Pediatric Population. Ann Pak Inst Med Sci. 2021;17(2):146–150. doi: 10.48036/apims.v17i2.456

Metz DK, Kausman JY. Childhood nephrotic syndrome in the 21st century: What’s new? J Paediatr Child Health. 2015;51(5):497–504. doi: 10.1111/jpc.12734.

Ali SH, Hussien FS, Abd Al-Amer H. Profile of renal diseases in Iraqi children: A single-center report. Saudi J Kidney Dis Transpl. 2015;26(3):613–618. doi: 10.4103/1319-2442.157422.

Hasan FO, AlUbaidy MSF, Murad HS. Outcome of idiopathic steroid resistant nephrotic syndrome of children in central child teaching hospital. Karbala J Med. 2022;15(1):2587–2595.

Abd Alridha AM, Kadhim D, Alkhazrajy A. The potential of vitamin-D-binding protein as a urinary biomarker to distinguish steroid-resistant from steroid-sensitive idiopathic nephrotic syndrome in Iraqi children. Siriraj Med J. 2023;75(4):248–258. doi: 10.33192/smj.v75i4.260831.

Lee JM, Ahn YH, Lim SH, Kang HG. Biomarkers predicting treatment-response in nephrotic syndrome of children: A systematic review. Child Kidney Dis. 2021;25(2):92–111. doi: 10.3339/jkspn.2021.25.2.92.

Abd Alridha AM, Kadhim DJ, Alkhazrajy AHA. A cross-sectional study of urinary neutrophil gelatinase-associated lipocalin and its association with steroid responsiveness in Iraqi children with idiopathic nephrotic syndrome. J Fac Med Baghdad. 2023;65(3):163–172.doi: 10.32007/jfacmedbagdad.2049.

Schijvens AM, Ter Heine R, de Wildt SN, Schreuder MF. Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome. Pediatr Nephrol. 2019;34(3):389–403. doi: 10.1007/s00467-018-3929-z.

Laing RE, Hess P, Shen Y, Wang J, Hu SX. The role and impact of SNPs in pharmacogenomics and personalized medicine. Curr Drug Metab. 2011;12(5):460–486.doi: 10.2174/138920011795495268.

Abd Alridha AM, Al-Gburi KM, Abbood SK. A Review of pharmacogenetics of anticoagulant therapy: Heparins, rivaroxaban, apixaban, and dabigatran. Med J Babylon. 2022;19(3):332–40. doi: 10.4103/MJBL.MJBL_71_22.

Abd Alridha AM, Al-Gburi K, Abbood SK. Warfarin therapy and pharmacogenetics: A narrative review of regional and Iraqi studies. Med J Babylon. 2022;19(3):324–331. doi: 10.4103/MJBL.MJBL_70_22.

Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol. 2003;43:285–307. doi: 10.1146/annurev.pharmtox.43.100901.140233.

Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics. 2003;4(4):397–410. doi: 10.1517/phgs.4.4.397.22747.

Bossennec M, Di Roio A, Caux C, Ménétrier-Caux C. MDR1 in immunity: friend or foe? Oncoimmunology. 2018;7(12):e1499388. doi: 10.1080/2162402X.2018.1499388.

Cuzzoni E, De Iudicibus S, Franca R, Stocco G, Lucafò M, Pelin M, et al. Glucocorticoid pharmacogenetics in pediatric idiopathic nephrotic syndrome. Pharmacogenomics. 2015;16(14):1631–1648. doi: 10.2217/pgs.15.101.

Parvin MN, Aziz MA, Rabbi SNI, Al-Mamun MMA, Hanif M, Islam MS, et al. Assessment of the Link of ABCB1 and NR3C1 gene polymorphisms with the prednisolone resistance in pediatric nephrotic syndrome patients of Bangladesh: A genotype and haplotype approach. J Adv Res. 2021;33:141–151. doi: 10.1016/j.jare.2021.02.001.

Han SS, Xu YQ, Lu Y, Gu XC, Wang Y. A PRISMA-compliant meta-analysis of MDR1 polymorphisms and idiopathic nephrotic syndrome: Susceptibility and steroid responsiveness. Medicine (Baltimore). 2017;96(24):e7191. doi: 10.1097/MD.0000000000007191.

Breitenstein B, Brückl TM, Ising M, Müller-Myhsok B, Holsboer F, Czamara D. ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2015;168B(4):274–283. doi: 10.1002/ajmg.b.32309.

Shan XX, Qiu Y, Xie WW, Wu RR, Yu Y, Wu HS, et al. ABCB1 gene is associated with clinical response to SNRIs in a local Chinese Han population. Front Pharmacol. 2019;10:761. doi: 10.3389/fphar.2019.00761.

Krupoves A, Mack D, Seidman E, Deslandres C, Amre D. Associations between variants in the ABCB1 (MDR1) gene and corticosteroid dependence in children with Crohn’s disease. Inflamm Bowel Dis. 2011;17(11):2308–2317.doi: 10.1002/ibd.21608.

Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629–637. doi: 10.1681/ASN.2008030287.

Musafer KNJ, Huyop FZ, Ewadh MJ, Supriyanto E, Al-Thuwaini TM, Al-Shuhaib MBS. The single nucleotide polymorphisms rs11761556 and rs12706832 of the leptin gene are associated with type 2 diabetes mellitus in the Iraqi population. Arch Biol Sci. 2021;73(1):93–101. doi: 10.2298/ABS210129005M.

Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15(2):97–98. doi: 10.1038/sj.cr.7290272.

Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, et al. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res. 2009;19(4):519–523. doi: 10.1038/cr.2009.33.

Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35(8):1529–1561. doi: 10.1007/s00467-020-04519-1.

Tullus K, Webb H, Bagga A. Management of steroid-resistant nephrotic syndrome in children and adolescents. Lancet Child Adolesc Health. 2018;2(12):880–890.doi: 10.1016/S2352-4642(18)30283-9.

Youssef DM, Attia TA, El-Shal AS, Abduelometty FA. Multi-drug resistance-1 gene polymorphisms in nephrotic syndrome: impact on susceptibility and response to steroids. Gene. 2013;530(2):201–207. doi: 10.1016/j.gene.2013.08.045.

Gooding JR, Agrawal S, McRitchie S, Acuff Z, Merchant ML, Klein JB, et al. Predicting and defining steroid resistance in pediatric nephrotic syndrome using plasma metabolomics. Kidney Int Rep. 2020;5(1):81–93. doi: 10.1016/j.ekir.2019.09.010.

Reference SNP (rs) Report: rs2032583 [Report on the Internet]. The National Center for Biotechnology Information. dbSNP Short Genetic Variations. 2022 [cited 2024 Feb 11]. Available from: https://www.ncbi.nlm.nih.gov/snp/rs2032583

Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM. Silent polymorphisms speak: How they affect pharmacogenomics and the treatment of cancer. Cancer Res. 2007;67(20):9609–12. doi: 10.1158/0008-5472.CAN-07-2377.

Reference SNP (rs) Report: rs2032582 [Internet]. The National Center for Biotechnology Information. dbSNP Short Genetic Variations. 2022 [cited 2024 Jun 10]. Available from: https://www.ncbi.nlm.nih.gov/snp/rs2032582#frequency_tab

Cizmarikova M, Podracka L, Klimcakova L, Habalova V, Boor A, Mjzis J, et al. MDR1 polymorphisms and idiopathic nephrotic syndrome in Slovak children: preliminary results. Med Sci Monit. 2015;21:59–68. doi: 10.12659/MSM.891366.

Choi HJ, Cho HY, Ro H, Lee SH, Han KH, Lee H, et al. Polymorphisms of the MDR1 and MIF genes in children with nephrotic syndrome. Pediatr Nephrol. 2011;26(11):1981–1988. doi: 10.1007/s00467-011-1903-0.

Abd Alridha AM, Kadhim DJ, Alkhazrajy AHA. Association of the rs118503 and rs1045642 polymorphisms in the MDR-1 gene with steroid responsiveness in Iraqi children with idiopathic nephrotic syndrome. Pharm Sci Asia. 2023;50(3):187–195. doi: 10.29090/psa.2023.03.23.245.

Yates CM, Sternberg MJE. The Effects of Non-synonymous single nucleotide polymorphisms (nsSNPs) on protein–protein interactions. J Mol Biol. 2013;425(21):3949–3963. doi: 10.1016/j.jmb.2013.07.012.